This study provides a novel therapeutic strategy for high-risk pregnant women with antiphospholipid syndrome (APS) and lupus anticoagulant (LA), suggesting that adding the TNF-α inhibitor certolizumab pegol to standard anticoagulation therapy can significantly reduce placenta-mediated adverse pregnancy outcomes. It offers high-quality evidence for future applications of immunomodulatory interventions in preventing recurrent miscarriage and preterm birth.
Literature Overview
The article titled 'Certolizumab pegol to prevent adverse pregnancy outcomes in patients with antiphospholipid syndrome and lupus anticoagulant (IMPACT): results of a prospective, single arm, open-label, phase 2 trial,' published in the journal Annals of the Rheumatic Diseases, systematically investigates the efficacy and safety of adding certolizumab pegol to standard therapy in pregnant women with antiphospholipid syndrome (APS) who are positive for lupus anticoagulant (LA). Using a prospective, single-arm design, this study is the first to evaluate the potential of TNF-α inhibitors in preventing severe preeclampsia and placental insufficiency, addressing the critical gap in effective immunomodulatory treatments for high-risk APS patients.Background Knowledge
Antiphospholipid syndrome (APS) is an autoimmune disorder characterized by thrombosis and adverse pregnancy outcomes (APO). In patients positive for lupus anticoagulant (LA), the risk of placenta-mediated APO remains high (39–86%) even with standard treatment using low-molecular-weight heparin (LMWH) and low-dose aspirin (LDA). Current APS management focuses primarily on anticoagulation, often overlooking the central role of placental inflammation. Research indicates that TNF-α is a key mediator of placental dysfunction, and blocking TNF-α in animal models can reverse fetal loss and preeclampsia-like symptoms. However, traditional IgG-type biologics can cross the placenta via Fc receptors, potentially affecting the fetal immune system. Therefore, certolizumab pegol—a TNF-α inhibitor lacking an Fc fragment—is an ideal candidate due to its minimal placental transfer and theoretically improved safety profile. This study addresses this mechanistic challenge by initiating certolizumab pegol early in pregnancy to block inflammation-driven placental injury and improve pregnancy outcomes.
Research Methods and Experiments
The study employed a single-arm, open-label, phase 2 clinical trial design (IMPACT trial), enrolling 51 pregnant women with confirmed APS and positive LA, all at less than 8 weeks of gestation. All participants received standard therapy (LMWH + LDA) and were additionally treated with certolizumab pegol between weeks 8 and 28 of pregnancy (initial dose: 400 mg subcutaneously, repeated at weeks 2 and 4, followed by 200 mg every two weeks). The primary endpoint was a composite adverse pregnancy outcome (APO), defined as fetal death at ≥10 weeks, severe preeclampsia, or preterm delivery before 34 weeks due to placental insufficiency. The historical APO rate was set at 40%, with a target sample size of 45 patients; efficacy would be declared if ≤12 APO events occurred. Safety assessments included infections, SLE flares, and neonatal outcomes. Data were analyzed using intention-to-treat (ITT), modified intention-to-treat (mITT), and per-protocol (PP) populations.Key Conclusions and Perspectives
Research Significance and Prospects
This study challenges the conventional reliance on anticoagulation alone in APS management by highlighting the central role of inflammation in placental dysfunction, thus promoting a paradigm shift from 'antithrombotic' to 'anti-inflammatory' strategies. Future studies should include multicenter, randomized, double-blind, placebo-controlled phase 3 trials to further validate the efficacy and safety of certolizumab pegol. Additionally, identifying biomarkers predictive of treatment response—such as TNF-α levels or inflammatory cytokine profiles—could enable personalized therapy. Moreover, these findings open new avenues for immunomodulatory interventions in other placenta-mediated pregnancy complications (e.g., preeclampsia, fetal growth restriction), potentially extending benefits to broader high-risk pregnant populations.
Conclusion
This study marks a significant advancement in the management of pregnancy in antiphospholipid syndrome. By introducing the TNF-α inhibitor certolizumab pegol alongside standard anticoagulation therapy, the research team successfully reduced the rate of adverse pregnancy outcomes in high-risk APS patients from over 40% in historical controls to 20%, without significant safety concerns. These results not only offer new hope for APS patients with recurrent miscarriages or preterm birth but also establish the feasibility of inflammation-targeted immunomodulation during pregnancy. Bridging laboratory findings to clinical application, this study lays the foundation for developing precise interventions against placental inflammation and may reshape the care framework for high-risk pregnancies in the future, ultimately improving maternal and neonatal outcomes. Future research should focus on confirming efficacy, identifying responders, and exploring its potential application in other inflammation-related pregnancy disorders.
